News

Monoclonal antibodies developed by a team of scientists at the NYU Langone Medical Center’s Center for Cognitive Neurology may be a stepping-stone towards potential new treatments against neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. The majority of neurodegenerative diseases, such as Alzheimer’s, Lewy Body and other dementias, Parkinson’s and prion diseases…

Accera, Inc. a clinical-stage biotechnology company based in Broomfield, Colorado, recently announced that 75% of patients have been enrolled in its NOURISH AD Phase 3 clinical trial assessing the efficacy of its investigational compound AC-1204 for the treatment of Alzheimer’s disease (AD). The company is expecting to enroll a total…

The Alzheimer’s Association and the Paul G. Allen Family Foundation recently announced the award of three grants to assess the role of the immune system in Alzheimer’s disease. The awards represent an investment of $500,000 to advance this understudied yet immense area of scientific knowledge, which could play a major role…

Researchers from Columbia University Medical Center (CUMC) have released multiple study findings showing that long term memories are stored with the help of prion-like proteins called CPEB.  These CPEB proteins work to form long term memory in the same way as the mechanisms that cause mad cow disease, kuru, and other…

Alzheimer’s disease is responsible for up to 70% of cases of dementia. It is a chronic neurodegenerative disease that usually starts with difficulty remembering recent events. It is often a patient’s family member that notices this loss of function and that urges the patient to see the doctor. Presently, there…

In a new study entitled “Novel DNA repair mechanism brings new horizons: Researchers discover new mechanism of DNA repair, which will help to treat and to prevent diseases in the future” researchers discovered a new mechanism on how the DNA molecule repairs itself which may translate into…